Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2017/07/008997
CTRI/2017/07/008997
Recruiting
Phase 2

Single arm prospective study evaluating the role of neoadjuvant chemotherapy in soft tissue sarcoma

AIIMS New Delhi0 sites25 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHealth Condition 1: null- patients with unresectable soft tissue sarcoma

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Health Condition 1: null- patients with unresectable soft tissue sarcoma
Sponsor
AIIMS New Delhi
Enrollment
25
Status
Recruiting
Last Updated
4 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
AIIMS New Delhi

Eligibility Criteria

Inclusion Criteria

  • •Either gender with age \>\=18 years
  • •Non\-metastatic histologically proven soft tissue sarcoma
  • •Chemotherapy naïve upfront or locally recurrent tumor which is either unresectable or resectable with an undesirable outcome
  • •Tumor size \>\= 5 cm \+ grade II/III
  • •ECOG PS \<\= 2
  • •Normal organ function (cardiac, liver, renal)

Exclusion Criteria

  • •Patients who refuse to give a written informed consent
  • •Histology like Ewingâ??s sarcoma, DFSP, epitheloid sarcoma, osteosarcoma,
  • •chondrosarcomas, alveolar soft part sarcoma, well differentiated liposarcoma,
  • •Rhabdomyosarcoma

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Phase 2
Clinical study of Agnikarma by Pippali in MigraineHealth Condition 1: G431- Migraine with aura
CTRI/2023/03/050429Dr Juned Aslam Kothali
Not yet recruiting
Phase 2
to know the effect of chatusama syurp in atisara in pre school age childreHealth Condition 1: R197- Diarrhea, unspecified
CTRI/2019/07/020035parul university
Completed
Phase 3
A prospective single arm study to assess the efficacy and safety of deferasirox in transfusion dependent beta-thalassemia patients unresponsive to current treatment or with intolerance to single dose therapyThalassemia.Beta thalassaemia
IRCT2014122920051N1ovartis40
Active, not recruiting
Phase 1
Single-arm study to assess a potential effect of anti-IL-17 (Secukinumab) in the treatment of pyoderma gangrenosuPyoderma gangrenosum is an autoinflammatory disease, characterized by relapsing, painful ulcers of the skin. Treatment of PG is difficult. Patients suffer from long hospitalization, pain and reduced life quality. New therapeutic strategies are needed. Immunohistological staining show a high amount of IL-17 in PG. IL-17+ immune cells were located in proximity to cellular damage, indicating an involvement in the pathogenesis. Targeting IL-17 with neutralizing IL-17 antibodies seems promising.MedDRA version: 20.0Level: PTClassification code 10037635Term: Pyoderma gangrenosumSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersTherapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
EUCTR2015-000762-65-DETechnische Universität München, School of Medicine, represented by Dean7
Not yet recruiting
Phase 2
Study held to see the effect of intake of nagbala milk decoction in treatment of high blood pressureHealth Condition 1: I10- Essential (primary) hypertension
CTRI/2020/11/028833Samkit Shah